purine/hitasótt

Krækjan er vistuð á klemmuspjaldið

Veldu tegund tegund

11 niðurstöður

Encorafenib Plus Binimetinib for People With BRAF V600E Mutated Relapsed/Refractory HCL

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Background: - Hairy cell leukemia (HCL) is an indolent B-cell leukemia comprising 2% of all leukemias, or approximately 1900 new cases/year in the US. The nucleoside analogs cladribine and pentostatin are highly active as monotherapy with complete remission (CR) rates of 80 to 90%. However, there is

Title: Moxetumomab Pasudotox-tdfk (Lumoxiti ) and Rituximab (Rituxan ) for Relapsed Hairy Cell Leukemia

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Background: - Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias, or approximately 1200 of the 62,130 new cases of leukemia/year in the US. HCL variant (HCLv), also CD22+, is 10-20% as common as HCL, but more common in the relapsed/refractory population due

Uric Acid Effects on Endothelium and Oxydative Stress

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

The goals of the research protocol are to clearly untie the respective roles of uric acid (UA) and xanthine oxidoreductase (XOR) pathways on endothelial function and oxidative stress in humans. UA represents the end-product of purine metabolism due to the loss of uricase 15 million years ago in

Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Background Chronic cold agglutinin disease (CAD) is mediated by monoclonal cold-reactive autoantibodies that bind to erythrocyte surface antigens, causing hemagglutination and complement-mediated hemolysis. Anemia is severe in one-third of patients (hemoglobin level 8.0 g/dL or lower). Cold-induced

A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Crohn's disease (CD) is a chronic inflammatory disease of the small bowel and colon. Symptoms commonly include bloody diarrhea, abdominal pain, weight loss, and fever. There is no known cause or cure for CD. The aim of current CD treatments is to induce and maintain remission, to reduce the need of

An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Ulcerative colitis (UC) is a chronic inflammatory disease of the colon. Symptoms include bloody diarrhea, weight loss, and fever. There is no known cause or cure for UC. The aim of current UC treatments is to induce and maintain remission, to reduce the need of corticosteroids and avoid

Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Illness: treatment overview Chronic lymphocytic leukemia (B-CLL) is the most prevalent adult leukemia among western countries (6.7% Non-Hodgkin Lymphomas- NHL). The incidence rate is 2-6 cases per 100.000 person per year increasing with age and reaching an incidence rate of about 13/100.000 at 65

Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world. The disease mostly affects the elderly. At present no curative therapy is available. Although the majority of patients initially do respond to chemotherapy, most patients eventually develop drug resistance. The

Therapy for Chronic Cold Agglutinin Disease

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

1. Background Chronic cold agglutinin disease (CAD) is mediated by monoclonal cold-reactive autoantibodies that bind to erythrocyte surface antigens, causing haemagglutination and complement-mediated haemolysis. Anaemia is severe (Hb 8.0 g/dL or lower) in one-third of patients and complement-induced

Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

There are multiple secondary objectives in this trial: - To estimate the overall event-free survival of patients treated with risk-directed therapy - To identify the plasma methotrexate (MTX) concentrations that produce maximum intracellular accumulation of active metabolites (methotrexate

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Background: It is estimated that 30-50% of patients with CLL have tumors that express cluster of differentiation 25 (CD25) (Tac or IL2R). Normal resting T-cells are not sensitive to LMB-2 due to insufficient CD25 expression. LMB-2 is an anti-CD25 recombinant immunotoxin containing variable domains

Skráðu þig á
facebook síðu okkar

Herbal & Natural Medicine

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum

Virkar á 55 tungumálum
Jurtalækningar studdir af vísindum
Jurtaviðurkenning eftir ímynd
Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
Lestu vísindarit sem tengjast leit þinni
Leitaðu að lækningajurtum eftir áhrifum þeirra
Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum

Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum